We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 1,283

FC Bifurcates Infringement & Validity Issues from Section 8 PM(NOC) Proceeding in Hopes of Settlement
  • PCK Perry + Currier Inc Currier + Kao LLP
  • Canada
  • August 22 2016

It appears that Courts look to reduce duplicative pharmaceutical litigation in PM(NOC) proceedings and related patent infringement actions by looking

Canadian Patent Appeal Board Upholds Claims to Non-exemplified Humanized Antibodies
  • Borden Ladner Gervais LLP
  • Canada
  • August 9 2016

In a rare and long-awaited piece of good news for antibody patent applications in Canada, the Patent Appeal Board ("the Board") recently allowed

Biosimilars in Canada: at a tipping point
  • Osler Hoskin & Harcourt LLP
  • Canada
  • May 24 2016

Biosimilars, or highly similar versions of innovative biologic medicines, have now been approved and marketed in developed countries for several

CIALIS Patent Survives Validity Challenge on Appeal
  • McCarthy Tétrault LLP
  • Canada
  • May 19 2016

Last year we wrote about a trilogy of Federal Court decisions relating to Eli Lilly’s erectile dysfunction (ED) drug CIALIS (tadalafil). While Lilly

Apotex Inc. v. Merck & Co. Inc., 2011 FCA 364 lovastatin; appeal from s.8 case
  • Gowling WLG
  • Canada
  • April 3 2012

In a decision is dated December 20, 2011 (but not released until recently), the Court of Appeal has overturned the Court’s finding that s. 8 of the 1993 NOC Regulations and found that the underlying NOC Regulation proceeding was “pending” at the time of the amendment of the NOC Regulations in 1998 as an appeal had been heard by the Supreme Court at that time and a decision was under reserve

Bifurcation of Infringement and Validity Issues in Section 8 Action
  • Borden Ladner Gervais LLP
  • Canada
  • August 10 2016

This is a motion for bifurcation in an action brought pursuant to section 8 of the Patented Medicines (Notice of Compliance) Regulations

Amgen’s cinacalcet application dismissed based on failure to meet selection patent criteria
  • Gowling WLG
  • Canada
  • November 19 2015

Justice Phelan has dismissed an application by Amgen to prohibit the Minister of Health from issuing a Notice of Compliance to Mylan for Amgen’s

Rx IP Update: 2015 Highlights
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • January 4 2016

In November 2014, Apotex discontinued its appeal to the Supreme Court of Canada (SCC) on the eve of the hearing of its appeal regarding the validity

The TPP new rights for pharmaceutical patent holders in Canada
  • Gowling WLG
  • Canada
  • November 13 2015

The Canadian Government released the official consolidated text of the Trans-Pacific Partnership (TPP) agreement on Nov., 5, 2015. This follows the

Obviousness double patenting in Canada not so obvious
  • SIM. IP Practice
  • Canada
  • May 16 2016

The recent decision of the Federal Court of Appeal in Mylan Pharmaceuticals ULC v. Eli Lilly Canada Inc. et al.,2016 FCA 119 ("Mylan"), highlights